AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer

Too Little, Too Late In Crowded Market

The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.

Astrazeneca
AstraZeneca is the market leader in EGFR-positive lung cancer, but trails far behind Merck and BMS in the PD-1/PD-L1 market.

AstraZeneca’s Imfinzi and tremelimumab combination with chemotherapy has achieved success in extending lives in first-line non-small cell lung cancer (NSCLC) patients, but has failed to match the performance of rival leading immunotherapies.

The Phase III POSEIDON results are a long-awaited victory after a string of failures for the combination, but will not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip